Table 2. Temporal trends of prescription of antithrombotic therapy among patients with atrial fibrillation undergoing percutaneous coronary intervention.
| Overall population | |||||||||||
| Year | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | ptrend |
| Total patients | 2140 | 2446 | 2511 | 2553 | 2778 | 2713 | 2940 | 3157 | 3411 | 3631 | <0.001 |
| SAPT | 29 (1.4) | 10 (0.4) | 2 (0.1) | 6 (0.2) | 6 (0.2) | 11 (0.4) | 11 (0.4) | 22 (0.7) | 25 (0.7) | 25 (0.7) | 0.374 |
| DAPT | 1616 (75.5) | 1808 (73.9) | 1880 (74.9) | 1904 (74.6) | 1990 (71.6) | 1876 (69.1) | 2014 (68.5) | 2050 (64.9) | 2159 (63.3) | 2188 (60.3) | <0.001 |
| OAC monotherapy | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.0) | 0 (0.0) | 1 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0.974 |
| Dual therapy (OAC+APT) | 10 (0.5) | 4 (0.2) | 2 (0.1) | 2 (0.1) | 13 (0.5) | 2 (0.1) | 7 (0.2) | 14 (0.4) | 10 (0.3) | 31 (0.9) | 0.006 |
| Triple (warfarin) | 485 (22.7) | 624 (25.5) | 627 (25.0) | 641 (25.1) | 767 (27.6) | 820 (30.2) | 895 (30.4) | 995 (31.5) | 1118 (32.8) | 752 (20.7) | <0.001 |
| Triple (NOAC) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.0) | 3 (0.1) | 12 (0.4) | 76 (2.4) | 99 (2.9) | 635 (17.5) | <0.001 |
| High stroke riska | |||||||||||
| Year | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | ptrend |
| Total patients | 2058 | 2345 | 2410 | 2458 | 2646 | 2604 | 2851 | 3063 | 3294 | 3528 | <0.001 |
| SAPT | 28 (1.4) | 9 (0.4) | 2 (0.1) | 6 (0.2) | 6 (0.2) | 10 (0.4) | 10 (0.4) | 22 (0.7) | 24 (0.7) | 23 (0.7) | 0.449 |
| DAPT | 1556 (75.6) | 1729 (73.7) | 1804 (74.9) | 1832 (74.5) | 1884 (71.2) | 1788 (68.7) | 1937 (67.9) | 1977 (64.5) | 2068 (62.8) | 2106 (59.7) | <0.001 |
| OAC monotherapy | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.0) | 0 (0.0) | 1 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0.979 |
| Dual therapy (OAC+APT) | 10 (0.5) | 4 (0.2) | 2 (0.1) | 2 (0.1) | 11 (0.4) | 2 (0.1) | 7 (0.2) | 14 (0.5) | 9 (0.3) | 31 (0.9) | 0.006 |
| Triple (warfarin) | 464 (22.5) | 603 (25.7) | 602 (25.0) | 618 (25.1) | 743 (28.1) | 800 (30.7) | 884 (31.0) | 975 (31.8) | 1096 (33.3) | 737 (20.9) | <0.001 |
| Triple (NOAC) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.0) | 3 (0.1) | 12 (0.4) | 75 (2.4) | 97 (2.9) | 631 (17.9) | <0.001 |
| Male | |||||||||||
| Year | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | ptrend |
| Total patients | 1403 | 1578 | 1595 | 1646 | 1802 | 1782 | 1918 | 2078 | 2277 | 2457 | <0.001 |
| SAPT | 18 (1.3) | 6 (0.4) | 2 (0.1) | 5 (0.3) | 4 (0.2) | 7 (0.4) | 9 (0.5) | 13 (0.6) | 19 (0.8) | 19 (0.8) | 0.206 |
| DAPT | 1051 (74.9) | 1141 (72.3) | 1154 (72.4) | 1211 (73.6) | 1271 (70.5) | 1215 (68.2) | 1318 (68.7) | 1346 (64.8) | 1466 (64.4) | 1486 (60.5) | <0.001 |
| OAC monotherapy | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | - |
| Dual therapy (OAC+APT) | 7 (0.5) | 1 (0.1) | 1 (0.1) | 1 (0.1) | 7 (0.4) | 2 (0.1) | 4 (0.2) | 10 (0.5) | 7 (0.3) | 25 (1.0) | 0.002 |
| Triple (warfarin) | 327 (23.3) | 430 (27.2) | 438 (27.5) | 429 (26.1) | 520 (28.9) | 556 (31.2) | 584 (30.4) | 666 (32.1) | 721 (31.7) | 531 (21.6) | 0.001 |
| Triple (NOAC) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.1) | 3 (0.2) | 43 (2.1) | 64 (2.8) | 396 (16.1) | <0.001 |
| Female | |||||||||||
| Year | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | ptrend |
| Total patients | 737 | 868 | 916 | 907 | 976 | 931 | 1022 | 1079 | 1134 | 1174 | <0.001 |
| SAPT | 11 (1.5) | 4 (0.5) | 0 (0.0) | 1 (0.1) | 2 (0.2) | 4 (0.4) | 2 (0.2) | 9 (0.8) | 6 (0.5) | 6 (0.5) | 0.735 |
| DAPT | 565 (76.7) | 667 (76.8) | 726 (79.3) | 693 (76.4) | 719 (73.7) | 661 (71.0) | 696 (68.1) | 704 (65.2) | 693 (61.6) | 702 (59.8) | <0.001 |
| OAC monotherapy | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.1) | 0 (0.0) | 1 (0.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0.743 |
| Dual therapy (OAC+APT) | 3 (0.4) | 3 (0.3) | 1 (0.1) | 1 (0.1) | 6 (0.6) | 0 (0.0) | 3 (0.3) | 4 (0.4) | 3 (0.3) | 6 (0.5) | 0.685 |
| Triple (warfarin) | 158 (21.4) | 194 (22.4) | 189 (20.6) | 212 (23.4) | 247 (25.3) | 264 (28.4) | 311 (30.4) | 329 (30.5) | 397 (35.0) | 221 (18.8) | <0.001 |
| Triple (NOAC) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.1) | 2 (0.2) | 9 (0.9) | 33 (3.1) | 35 (3.1) | 239 (20.4) | <0.001 |
Abbreviations: APT, antiplatelet; DAPT, dual antiplatelet therapy; NOAC, non-vitamin K antagonist oral anticoagulant; OAC, oral anticoagulant; SAPT single antiplatelet therapy
Values are given as number (percentage), unless otherwise indicated.
aCHA2DS2-VASc score ≥2